Bosentan therapy of pulmonary arterial hypertension in connective tissue diseases

European Journal of Clinical Investigation

Volumn 36, Issue SUPPL. 3, 2006, Pages 49-53

  Cozzi, F ^a   Montisci, R ^a   Marotta, H ^a   Bobbo, F ^a   Durigon, N ^a   Ruscazio, M ^a   Sfriso, P ^a   Iliceto, S ^a   Todesco, S ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Bosentan; Connective tissue diseases; Exercise capacity; Pulmonary arterial hypertension

Indexed keywords

BOSENTAN; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; PROSTANOID;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONNECTIVE TISSUE DISEASE; DOPPLER ECHOGRAPHY; DRUG DOSE REDUCTION; DRUG EFFECT; EXERCISE TEST; FEMALE; HEMODYNAMIC MONITORING; HUMAN; LUNG ARTERY PRESSURE; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; SYSTOLIC BLOOD PRESSURE;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CONNECTIVE TISSUE DISEASES; EXERCISE TEST; FEMALE; HUMANS; HYPERTENSION, PULMONARY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MIXED CONNECTIVE TISSUE DISEASE; MYOSITIS; PROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; SULFONAMIDES; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, RIGHT; WALKING;

EID: 33746821078     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2006.01684.x     Document Type: Conference Paper

References (36)

1. Silver RM. Scleroderma. Clinical problems. The lungs. Rheum Dis Clin North Am 1996;22:825-40.
2. Denton CP, Black CM. Pulmonary hypertension in systemic sclerosis. Rheum Dis Clin N Am 2003;29:335-49.
3. Pan TL, Thumboo J, Boey ML. Primary and secondary pulmonary hypertension in systemic lupus erythematosus. Lupus 2000;9:338-42.
4. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343-59.
5. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003;123:344-50.
6. Koh E, Lee P, Gladman D, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Rheumatology 1996;35(10):989-93.
7. Highland KB, Strange C, Mazur J, Simpson KN. Treatment of pulmonary arterial hypertension: a preliminary decision analysis. Chest 2003;124:2087-92.
8. Mehta S. Drug therapy for pulmonary arterial hypertension: what's on the menu today? Chest 2003;124:2045-9.
9. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-36.
10. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296-302.
11. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000;132:425-34.
12. Hoeper MM, Schwarze M, Ehlerding S, Adler-Schuermeyer A, Spiekerkoetter E, Niedermeyer J et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000;342:1866-70.
13. Galiè N, Humbert M, Vachiery JL, Vizza CD, Kneussl M, Manes A et al. Arterial Pulmonary Hypertension and Beraprost European (ALPHABET) Study Group: Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002;39:1496-502.
14. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC et al. Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-4.
15. Kahaleh MB. Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action. Arthritis Rheum 1991;34:978-83.
16. Shi-Wen X, Denton CP, Dashwood MR, Holmes AM, Bou-Gharios G, Pearson JD et al. Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol 2001;116:417-25.
17. Hachulla E, Coghlan JG. A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism. Ann Rheum Dis 2004;63:1009-14.
18. Vancheeswaran R, Magoulas T, Efrat G, Wheeler-Jones C, Olsen I, Penny R et al. Circulating endothelin-1 levels in systemic sclerosis subsets - a marker of fibrosis or vascular dysfunction? J Rheumatol 1994;21:1838-44.
19. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119-23.
20. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;364:896-903.
21. Sitbon O, Badesch DB, Channick RN, Frost A, Robbins IM, Simonneau G et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003;124:247-54.
22. McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galie N et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005;25:244-9.
23. Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO, Taylor DW et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Ass J 1985;132:919-23.
24. Crapo RO, Casaburi R, Coates AL, Enright PL, MacIntyre NR, McKay RT. ATS statement: Guidelines for sixminutes walk test. Am J Respir Crit Care Med 2002;166:111-7.
25. Yock PG, Popp RL. Non invasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 1984;70:657-62.
26. Naeije R, Torbicki A. More on the non invasive diagnosis of pulmonary hypertension: Doppler echocardiography revisited. Eur Respir J 1995;8:1445-9.
27. Mahan G, Dabestani A, Gardin J, Allfie A, Burn C, Henry W. Estimation of pulmonary artery pressure by pulsed Doppler echocardiography. Circulation 1983;68:302-9.
28. McLaughlin V, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002;106:1477-82.
29. Oudiz RJ, Schilz RJ, Barst RJ. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 2004;126:420-7.
30. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ et al. Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-9.
31. Humbert M, Simonneau G. Sildenafil for pulmonary arterial hypertension: still waiting for evidence. Am J Respir Crit Care Med 2004;169:6-7.
32. Galie N, Manes A, Branzi A. Emerging medical therapies for pulmonary arterial hypertension. Prog Cardiovasc Dis 2002;45:213-24.
33. Channick RN, Sitbon O, Barst RJ, Manes A, Rubin LJ. Endothelin receptor antagonists in pulmonary arterial hypertension. Am Coll Cardiol 2004;43:62-7.
34. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Resp Crit Care Med 2000;161:487-92.
35. Merkel PA, Clements PJ, Reveille JD, Suarez-Almazor ME, Valentini G, Furst DE. Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. J Rheumatol 2003;30:1630-47.
36. Denton C, Coghlan J, Black CM, Hoeper MM, Kiely DG, Carlsen J et al. Long-term safety profile of bosentan in patients with systemic sclerosis and pulmonary arterial hypertension: results from the TRAX database. Ann Rheum Dis 2005;64 (Suppl. III): 294.